Overview

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

Status:
Unknown status

Trial end date:
2018-07-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS). The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Singapore General Hospital

Collaborators:

National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore
Singapore Clinical Research Institute
Sirtex Medical

Treatments:

Niacinamide
Sorafenib